HER-2 V777L
|
HER2 Negative Breast Cancer
|
HER-2 V777L
|
HER2 Negative Breast Cancer
|
neratinib Sensitive: C2 – Inclusion Criteria
|
neratinib Sensitive: C2 – Inclusion Criteria
|
HER-2 V777L
|
Breast Cancer
|
HER-2 V777L
|
Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
HER-2 V777L
|
Gastric Cancer
|
HER-2 V777L
|
Gastric Cancer
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 V777L
|
Breast Cancer
|
HER-2 V777L
|
Breast Cancer
|
ado-trastuzumab emtansine Resistant: D – Preclinical
|
ado-trastuzumab emtansine Resistant: D – Preclinical
|
HER-2 V777L
|
CRC
|
HER-2 V777L
|
CRC
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
trastuzumab + tucatinib Sensitive: D – Preclinical
|
HER-2 V777L
|
CRC
|
HER-2 V777L
|
CRC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 V777L
|
NSCLC
|
HER-2 V777L
|
NSCLC
|
tucatinib Sensitive: D – Preclinical
|
tucatinib Sensitive: D – Preclinical
|
HER-2 V777L
|
CRC
|
HER-2 V777L
|
CRC
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
HER-2 V777L
|
CRC
|
HER-2 V777L
|
CRC
|
panitumumab Resistant: D – Preclinical
|
panitumumab Resistant: D – Preclinical
|